DNTH
Dianthus Therapeutics, Inc.
$76.78
-2.23%
2026-10-23
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Key Fundamentals
Forward P/E
-19.20
EPS (TTM)
$-4.24
ROE
-26.1%
Revenue Growth (YoY)
294.3%
Profit Margin
0.0%
Debt/Equity
0.11
Price/Book
4.14
Beta
0.06
Market Cap
$4.84B
Avg Volume (10D)
1.1M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$117.88
60D Low
$69.43
Avg Volume
831K
Latest Close
$76.78
Get breakout alerts for DNTH
Sign up for Breakout Scanner to receive daily notifications when DNTH triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Dianthus Therapeutics, Inc. (DNTH) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors DNTH daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. DNTH operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.